REMI-AI Rapid Detection Module (REMI-AI RDM)

The REMI-AI Rapid Detection Module is a Class II physiological signal monitor designed for the automated, near real-time detection of potential electrographic seizures in non-ICU settings by analyzing EEG data. Its development involved rigorous validation, demonstrating substantial equivalence and meeting performance requirements for sensitivity and false alarm rates, establishing it as a safe and effective tool for alerting clinicians to seizure activity.

The REMI-AI Rapid Detection Module (REMI-AI RDM) is a Class II device designed to automatically detect potential electrographic seizures in near real-time by analyzing EEG data. Integrated with the REMI Remote EEG Monitoring System, it notifies qualified clinicians when a seizure prevalence of 10% or greater is identified within a 5-minute rolling window, indicating at least 30 seconds of activity, alongside a confidence measure. Intended for adult and pediatric patients aged 6 years and older in non-ICU healthcare settings, it functions as a physiological signal monitor, not a diagnostic tool, and is specifically not indicated for detecting electrographic status epilepticus.The device's safety and effectiveness were affirmed through a substantial equivalence determination against other legally marketed devices, supported by comprehensive development processes. This included rigorous software verification, interoperability testing, human factors validation, and clinical validation, which confirmed the device met its performance requirements for sensitivity and false alarm rates across diverse patient populations. Furthermore, it incorporates an authorized Predetermined Change Control Plan to streamline future algorithm improvements and remains subject to general controls and quality system regulations ensuring ongoing quality and compliance.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific EEG features or algorithms does the REMI-AI RDM utilize to detect seizures and determine the 10% prevalence threshold?; How does the "event detection confidence" metric influence clinical decision-making, and what are its performance characteristics (e.g., correlation with true positive rate)?; Given its non-diagnostic classification, how is the device's output integrated into existing clinical workflows to ensure timely and appropriate patient management without misinterpretation?; What was the typical duration of EEG monitoring sessions during clinical validation, and how might performance vary with longer or shorter monitoring periods?; What types of algorithm improvements are anticipated under the Predetermined Change Control Plan, and how will these updates be evaluated for their impact on clinical utility?